<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424979</url>
  </required_header>
  <id_info>
    <org_study_id>MPP_Feasibility1</org_study_id>
    <secondary_id>R01EY023385</secondary_id>
    <nct_id>NCT04424979</nct_id>
  </id_info>
  <brief_title>Feasibility Tests for Various Prism Configurations for Visual Field Loss</brief_title>
  <official_title>Visual Field Expansion Through Innovative Multi-Periscopic Prism Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will develop and test different configurations of high-power prisms to
      expand the field of vision of patients with visual field loss to assist them with obstacle
      detection when walking. The study will involve multiple visits (typically four) to Schepens
      Eye Research Institute for fitting and testing with the prism glasses. The overall objective
      is to determine best designs and fitting parameters for implementation in prism devices for
      future clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Field of view expansion</measure>
    <time_frame>Through study completion, an average of four months</time_frame>
    <description>Horizontal and vertical extent of the expansion (in degrees) of the field of view</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pedestrian detection rate</measure>
    <time_frame>Through study completion, an average of four months</time_frame>
    <description>Proportion of pedestrians detected (in simulated walking or simulated driving)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemianopia, Homonymous</condition>
  <condition>Tunnel Vision</condition>
  <condition>Visual Field Defect, Peripheral</condition>
  <condition>Visual Field Constriction Bilateral</condition>
  <condition>Visual Field Defect Homonymous Bilateral</condition>
  <arm_group>
    <arm_group_label>High power prisms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Various configurations of high power prisms will be developed for each individual and custom fit into spectacles lenses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High power prisms</intervention_name>
    <description>High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision</description>
    <arm_group_label>High power prisms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visual field loss, either peripheral field loss or hemianopic field loss

          -  Visual acuity of at least 20/50 in the better eye

          -  In sufficiently good health to be able to complete sessions lasting 2-4 hours

          -  Able to independently walk short distances

          -  Able to give voluntary, informed consent

          -  Able to speak English

        Exclusion Criteria:

          -  Any physical or mental impairments, including cognitive dysfunction, balance problems
             or other deficits that could impair the ability to walk or use the prism spectacles

          -  A history of seizures in the last 6 months

          -  Hemispatial neglect (subjects with hemianopic field loss only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliezer Peli, MSc, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schepens Eye Research Institute of Massachusetts Eye and Ear</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sailaja Manda</last_name>
    <phone>617 912 2522</phone>
    <email>sailaja_manda@meei.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alex Bowers, PhD</last_name>
    <phone>617 912 2512</phone>
    <email>alex_bowers@meei.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Eliezer Peli</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>Visual field expansion</keyword>
  <keyword>Prisms</keyword>
  <keyword>Hemianopsia</keyword>
  <keyword>Tunnel vision</keyword>
  <keyword>Visual field loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemianopsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

